Jiangsu HengRui Medicine Co., Ltd.
Works in Cardiovascular · Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Renal & urogenital · Respiratory · Women's health
Jiangsu HengRui Medicine Co., Ltd. is a clinical trial sponsor. It has 92 active clinical trials with 29,914 planned participants, across 16 therapeutic areas. Since 2021 it has completed 214 trials and stopped 31 early.
Trial track record · since 2021
Pipeline · 92 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Jiangsu HengRui Medicine Co., Ltd
Jiangsu HengRui Medicine Co., Ltd is lead sponsor of 92 active clinical trials on ClinicalTrials.gov, with 29,914 planned participants, in Cardiovascular, Dermatology, ENT, Genetic & rare and other areas. Since 2021 it has completed 214 trials and stopped 31 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Jiangsu HengRui Medicine Co., Ltd; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-23.
Approve Suite is not affiliated with Jiangsu HengRui Medicine Co., Ltd..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.